Drug Profile
Research programme: inflammation therapeutics - Akari Therapeutics
Alternative Names: Bioengineered tick salivary proteins - Akari Therapeutics; CFX-1; MCF; MRX-5; OPRX; OPT 1; OPX-1; Orally absorbed C5 inhibitor - Akari Therapeutics; Tick derived anti-inflammatory compounds - Akari Therapeutics; Tick derived proteins - Akari Therapeutics; Tissue specific proteins - Akari TherapeuticsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Morria Biopharmaceuticals
- Developer Akari Therapeutics
- Class Anti-inflammatories; Antihistamines; Proteins
- Mechanism of Action Arachidonic acid inhibitors; Complement system protein inhibitors; Histamine receptor antagonists; Inflammation mediator inhibitors; Leukotriene B4 inhibitors; Phospholipase A2 inhibitors; Serotonin receptor antagonists; Thromboxane A2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic conjunctivitis; Cystic fibrosis; Dry eyes; Eye disorders; Inflammation; Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Inflammation in United Kingdom
- 28 Feb 2021 No recent reports of development identified for preclinical development in Inflammation in United Kingdom (PO)
- 04 Jan 2017 Preclinical trials of a C5 inhibitor in Inflammation in United Kingdom (PO)